Personas / Equipo Humano

Emma Barroso Fernández

Buscador de publicaciones

Publicaciones

  • Zhang M, Barroso E, Ruart M, Peña L, Peyman M, Aguilar-Recarte D, Montori M, Rada P, Cugat C, Montironi C, Zarei M, Jurado-Aguilar J, Camins A, Balsinde J, Valverde ÁM, Wahli W, Palomer FX and Vazquez M.

    Elafibranor upregulates the EMT-inducer S100A4 via PPARß/d

    BIOMEDICINE & PHARMACOTHERAPY . 167: 115623-115623. Nº de citas: 3

    [doi:10.1016/j.biopha.2023.115623]

  • Zhang M, Bagán A, Martínez D, Barroso E, Palomer FX, Vázquez S, Escolano C and Vazquez M.

    Design and Synthesis of AMPK Activators and GDF15 Inducers

    Molecules . 28(14): .

    [doi:10.3390/molecules28145468]

  • Barroso E, Montori M, Wahli W, Palomer FX and Vazquez M.

    Striking a gut-liver balance for the antidiabetic effects of metformin

    TRENDS IN PHARMACOLOGICAL SCIENCES . 44(7): 457-473. Nº de citas: 5

    [doi:10.1016/j.tips.2023.04.004]

  • Aguilar-Recarte D, Barroso E, Zhang M, Rada P, Pizarro J, Peña L, Palomer FX, Valverde ÁM, Wahli W and Vazquez M.

    A positive feedback loop between AMPK and GDF15 promotes metformin antidiabetic effects.

    PHARMACOLOGICAL RESEARCH . 187: 106578-106578. Nº de citas: 17

    [doi:10.1016/j.phrs.2022.106578]

  • Aguilar-Recarte D, Barroso E, Palomer FX, Wahli W and Vazquez M.

    Knocking on GDF15?s door for the treatment of type 2 diabetes mellitus

    TRENDS IN ENDOCRINOLOGY AND METABOLISM . 33(11): 741-754. Nº de citas: 19

    [doi:10.1016/j.tem.2022.08.004]

  • García-Torra V, Cano A, Espina M, Ettcheto M, Camins A, Barroso E, Vazquez M, García ML, Sánchez-López E and Souto EB.

    State of the Art on Toxicological Mechanisms of Metal and Metal Oxide Nanoparticles and Strategies to Reduce Toxicological Risks.

    Toxics . 9(8): 195. Nº de citas: 21

    [doi:10.3390/toxics9080195]

  • Aguilar-Recarte D, Barroso E, Gumá L, Pizarro J, Peña L, Ruart M, Palomer FX, Wahli W and Vazquez M.

    GDF15 mediates the metabolic effects of PPARß/d by activating AMPK.

    CELL REPORTS . 36(6): 109501-109501. Nº de citas: 53

    [doi:10.1016/j.celrep.2021.109501]

  • Barroso E, Rodríguez-Rodríguez R, Zarei M, Pizarro-Degado J, Planavila A, Palomer FX, Villarroya-Gombau F and Vazquez M.

    SIRT3 deficiency exacerbates fatty liver by attenuating the HIF1 alpha-LIPIN 1 pathway and increasing CD36 through Nrf2

    CELL COMMUNICATION AND SIGNALING . 18(1): 147-147. Nº de citas: 27

    [doi:10.1186/s12964-020-00640-8]

  • Zarei M, Pizarro J, Barroso E, Palomer FX and Vazquez M.

    Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis

    TRENDS IN PHARMACOLOGICAL SCIENCES . 41(3): 199-208. Nº de citas: 69

    [doi:10.1016/j.tips.2019.12.005]

  • Palomer FX, Román-Azcona MS, Pizarro J, Planavila A, Villarroya-Gombau F, Valenzuela-Alcaraz BI, Crispi F, Sepúlveda-Martínez Á, Miguel-Escalada I, Ferrer J, Nistal JF, García R, Davidson MM, Barroso E and Vazquez M.

    SIRT3-mediated inhibition of FOS through histone H3 deacetylation prevents cardiac fibrosis and inflammation.

    signal transduction and targeted therapy . 5(1): 14-14. Nº de citas: 111

    [doi:10.1038/s41392-020-0114-1]